AI心电图用于肥厚型心肌病检测的临床实施
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is often underdiagnosed. Artificial intelligence (AI)-based notification of HCM suspicion on a 12-lead ECG has been proposed to assist patient identification and evaluation.…
要点
- AI心电图提示疑似HCM后用户查看率为69%(3017/4348)。
- 入组217例中17例(7.8%)新诊断HCM,其中住院8例、门诊9例。
- 优化算法工作点使提示比例从4.4%降至2.3%(p<0.0001)。
核心结论
- 基于AI的心电图设备可在多种临床工作流程中成功实施,有助于识别新的HCM患者。
研究设计与样本
- 开放标签、多中心前瞻性队列研究,在5个医疗系统于2023年1–12月实施Viz HCM(Viz.ai)AI-ECG软件,筛查年龄>18岁且无既往HCM诊断的患者。
主要发现
- 用户查看了69%(3017/4348)的AI疑似HCM病例。
- 217例符合研究标准并入组,种族和族裔代表广泛,包括23%黑人、9%亚裔和12%西班牙裔或拉丁裔。
- 入组患者中182例(84%)有指征进行共243项随访行动。
- 从心电图到提示HCM的诊断影像学检查的中位(四分位距)时间为7.5(1.0–37.2)天。
关键数值与推荐
- 研究期间部署优化算法工作点使算法筛查患者的提示百分比从4.4%(2097/47868)降至2.3%(2251/97980),p<0.0001,且按查看提示的入组率无差异。
临床怎么用
- 可将AI-ECG用于提示疑似HCM以辅助患者识别和评估,并需关注提示查看率与随访行动衔接。
局限性
- 未来需要研究评估可扩展性并与标准诊疗进行比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is often underdiagnosed. Artificial intelligence (AI)-based notification of HCM suspicion on a 12-lead ECG has been proposed to assist patient identification and evaluation. However, there has been no study to date to assess clinical implementation of this approach. METHODS: In an open-label, multicentre prospective cohort study, Viz HCM (Viz.ai)-an AI-ECG software alerting of suspected HCM-was implemented at five healthcare systems between January and December 2023 to identify patients >18 years of age without prior HCM diagnosis. The coprimary endpoints were the percentage of HCM-suspected cases viewed by users and the types of follow-up actions. Additional outcome measures included the time to follow-up, demographic characteristics of enrolled patients and follow-up outcomes. RESULTS: Out of 145 848 patients screened with algorithm-compliant ECGs, 4348 (3%) were alerted for suspected HCM. Users viewed 69% (3017/4348) of AI-suspected HCM cases. 217 patients met the study criteria and were enrolled with broad representation across racial and ethnic groups-including 23% Black, 9% Asian and 12% Hispanic or Latino. Of the enrolled patients, 182 (84%) had an indication for a total of 243 follow-up actions. The median (interquartile) time from ECG to diagnostic imaging indicating HCM was 7.5 (1.0-37.2) days. From the 217 enrolled patients, 17 (7.8%) were newly diagnosed with HCM-8 inpatient and 9 outpatient. During the study, deployment of an optimised algorithm operating point helped reduce the alert percentage of algorithm-screened patients from 4.4% (2097/47868) to 2.3% (2251/97980), p<0.0001, with no difference in the enrolment rate by alerts reviewed. CONCLUSION: An AI-based ECG device for HCM can be implemented successfully in a variety of clinical workflows to help identify new patients with HCM. Future study is warranted to assess scalability and comparisons to standard of care.
引用
- Love CJ, Lampert J, Huneycutt D, et al. Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection. Heart. 2025. PMID: 40240132. doi:10.1136/heartjnl-2024-325608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。